Navigation path

INYVAX


Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges
 
 
Framework programme:
 7
Contract/Grant agreement number:
223532
EC contribution:
932,335 €
Duration:
36 months
Funding scheme:
Coordination Action
Starting date:
01/02/2009
Web-site:
http://www.inyvax.eu
 
 

Keywords: malaria, vaccine, EMVI, EVI

Background

A number of new vaccines are being developed against poverty-related infectious diseases of major public health importance at global level. The development of these vaccines is facing the same kind of challenges and gaps, which still prevent the following: a) establishment of readily accessible formulation and scale-up process development capacity for neglected disease vaccines; b) establishment of a systematic approach for prioritising formulation of vaccine candidates using accepted preclinical criteria; c) development of information-sharing tools to strengthen connections between scientists, developers and clinical investigators.

The European vaccine community needs to establish both a shared vision and goals to identify the activities required to address these challenges. Cooperation between the different groups of PRD vaccine developers will bring innovative approaches for accelerating the development of effective vaccines. Several of these challenges, set out below, can be addressed through coordination:

  • difficulties in accessing some technology platforms, such as synthetic peptides/recombinant proteins and expertise for good manufacturing practice (GMP)development, therefore allowing rational decisions to be made based on the best industrial approach for pharmaceutical development;
  • difficulties in accessing certain types of knowledge and know-how, such as lyophilisation and lack of formulation platforms accessible to academic groups;
  • difficulties in accessing some delivery platforms, such as adjuvants and virus-like particles for GMP development and/or to assess the quality and regulatory compliance of those platforms;
  • difficulties in harmonising the safety data collection;
  • insufficient numbers of trained scientists able to undertake leadership roles in vaccine development.
[+] Read More